Ayman Elguindy, PhD

CEO and Co-founder, AbVir Biotherapeutics

Dr. Ayman El-Guindy, PhD, is Co-Founder and Chief Executive Officer of AbVir Biotherapeutics and a globally recognized leader in Epstein-Barr virus (EBV) and oncogenic viruses. He earned his doctorate at Yale University, training under world-renowned virologist Dr. George Miller, and went on to serve as an Assistant and later Associate Professor at Yale, where his laboratory made foundational contributions to understanding herpesvirus latency, reactivation, viral gene regulation, and the role of viral kinases in tumorigenesis. He later became Chief Scientific Officer at Viracta Therapeutics, a publicly traded company focused on EBV-associated diseases, where he led global R&D.

With more than 28 years of experience in virus–cancer research, Dr. El-Guindy has authored numerous peer-reviewed publications, led international collaborations, and served on editorial boards and scientific committees. He has been elected to the governing board of the International EBV Research Association and is an American Cancer Society Research Scholar, underscoring his recognition as a thought leader in the field.

As CEO of AbVir, Dr. El-Guindy drives both the scientific vision and strategic direction of the company, leveraging his deep academic connections and expertise in EBV biology to advance novel therapeutics with a first-in-class focus on preventing post-transplant lymphoproliferative disorder (PTLD) in transplant patients — a critical unmet medical need. His ability to bridge academia and industry, combined with a strong track record in regulatory strategy, IP development, fundraising, and scientific partnerships, positions him as both a scientific innovator and strategic business leader dedicated to delivering transformative EBV-targeted therapies to patients.